Search Results - "Mathijssen, R. H. J."

Applying a cost-based pricing model for innovative cancer treatments subject to indication expansion: A case study for pembrolizumab and daratumumab by Heine, R J S D, Thielen, F W, Mathijssen, R H J, van Leeuwen, R W F, Franken, M G, Uyl-de Groot, C A

“…Expanding the indication of already approved immuno-oncology drugs presents treatment opportunities for patients but also strains healthcare systems…”
Get full text

Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro–in vivo correlations by Hu, S, Mathijssen, R H J, de Bruijn, P, Baker, S D, Sparreboom, A

“…Background: Several tyrosine kinase inhibitors (TKIs) can decrease docetaxel clearance in patients by an unknown mechanism. We hypothesised that these…”
Get full text

The genomic and transcriptomic landscape of advanced renal cell cancer for individualized treatment strategies by de Joode, K., van de Geer, W. S., van Leenders, G. J. L. H., Hamberg, P., Westgeest, H. M., Beeker, A., Oosting, S. F., van Rooijen, J. M., Beerepoot, L. V., Labots, M., Mathijssen, R. H. J., Lolkema, M. P., Cuppen, E., Sleijfer, S., van de Werken, H. J. G., van der Veldt, A. A. M.

“…Differences in the clinical course and treatment responses in individual patients with advanced renal cell carcinoma (RCC) can largely be explained by the…”
Get full text

Association Analysis of Genetic Polymorphisms in Genes Related to Sunitinib Pharmacokinetics, Specifically Clearance of Sunitinib and SU12662 by Diekstra, M H M, Klümpen, H J, Lolkema, M P J K, Yu, H, Kloth, J S L, Gelderblom, H, van Schaik, R H N, Gurney, H, Swen, J J, Huitema, A D R, Steeghs, N, Mathijssen, R H J

“…Interpatient variability in the pharmacokinetics (PK) of sunitinib is high. Single nucleotide polymorphisms (SNPs) in PK candidate genes have been associated…”
Get full text

Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study by Crona, D J, Ramirez, J, Qiao, W, de Graan, A-J, Ratain, M J, van Schaik, R H N, Mathijssen, R H J, Rosner, G L, Innocenti, F

“…The overall goal of this study was to provide evidence for the clinical validity of nine genetic variants in five genes previously associated with irinotecan…”
Get full text

Environmental and Genetic Factors Affecting Transport of Imatinib by OATP1A2 by Eechoute, K, Franke, RM, Loos, WJ, Scherkenbach, LA, Boere, I, Verweij, J, Gurney, H, Kim, RB, Tirona, RG, Mathijssen, RHJ, Sparreboom, A

“…The bioavailability of orally administered imatinib is >90%, although the drug is monocationic under the acidic conditions in the duodenum. In vitro, we found…”
Get full text

Prevalence of potential drug–drug interactions in cancer patients treated with oral anticancer drugs by van Leeuwen, R W F, Brundel, D H S, Neef, C, van Gelder, T, Mathijssen, R H J, Burger, D M, Jansman, F G A

“…Background: Potential drug–drug interactions (PDDIs) in patients with cancer are common, but have not previously been quantified for oral anticancer treatment…”
Get full text

miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells by van Jaarsveld, M T M, Helleman, J, Boersma, A W M, van Kuijk, P F, van IJcken, W F, Despierre, E, Vergote, I, Mathijssen, R H J, Berns, E M J J, Verweij, J, Pothof, J, Wiemer, E A C

“…Epithelial ovarian cancer is the most lethal gynecological malignancy in the Western world. A major impediment for the successful treatment is the development…”
Get full text

Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer by van Soest, R.J, van Royen, M.E, de Morrée, E.S, Moll, J.M, Teubel, W, Wiemer, E.A.C, Mathijssen, R.H.J, de Wit, R, van Weerden, W.M

“…Abstract Introduction Treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC) have expanded in recent years with the…”
Get full text

The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer by van Soest, R.J, Nieuweboer, A.J.M, de Morrée, E.S, Chitu, D, Bergman, A.M, Goey, S.H, Bos, M.M, van der Meer, N, Hamberg, P, de Wit, R, Mathijssen, R.H.J

“…Abstract Introduction The treatment armamentarium for metastatic castration-resistant prostate cancer (mCRPC) has expanded with the introduction of several new…”
Get full text

Conventional Dosing of Anticancer Agents: Precisely Wrong or Just Inaccurate? by Bins, S, Ratain, M J, Mathijssen, R H J

Get full text

Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours by Lankheet, N A G, Kloth, J S L, Gadellaa-van Hooijdonk, C G M, Cirkel, G A, Mathijssen, R H J, Lolkema, M P J K, Schellens, J H M, Voest, E E, Sleijfer, S, de Jonge, M J A, Haanen, J B A G, Beijnen, J H, Huitema, A D R, Steeghs, N

“…Background: Plasma exposure of sunitinib shows large inter-individual variation. Therefore, a pharmacokinetic (PK) study was performed to determine safety and…”
Get full text

MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumours by Gits, C M M, van Kuijk, P F, Jonkers, M B E, Boersma, A W M, van IJcken, W F, Wozniak, A, Sciot, R, Rutkowski, P, Schöffski, P, Taguchi, T, Mathijssen, R H J, Verweij, J, Sleijfer, S, Debiec-Rychter, M, Wiemer, E A C

“…Background: Gastrointestinal stromal tumours (GIST) are characterised by high expression of KIT and ETV1, which cooperate in GIST oncogenesis. Our aim was to…”
Get full text

Pemetrexed exposure predicts toxicity in advanced non–small-cell lung cancer: A prospective cohort study by Visser, S., Koolen, S.L.W., de Bruijn, P., Belderbos, H.N.A., Cornelissen, R., Mathijssen, R.H.J., Stricker, B.H., Aerts, J.G.J.V.

“…We explored whether total exposure to pemetrexed predicts effectiveness and toxicity in advanced non–small-cell lung cancer (NSCLC). Furthermore, we…”
Get full text

Case Report: Adequate T and B Cell Responses in a SARS-CoV-2 Infected Patient After Immune Checkpoint Inhibition by de Joode, K, Oostvogels, A A M, GeurtsvanKessel, C H, de Vries, R D, Mathijssen, R H J, Debets, R, van der Veldt, A A M

“…After the COVID-19 outbreak, non-evidence based guidelines were published to advise clinicians on the adjustment of oncological treatment during this pandemic…”
Get full text

Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules by Hamberg, P., Mathijssen, R. H. J., de Bruijn, P., Leonowens, C., van der Biessen, D., Eskens, F. A. L. M., Sleijfer, S., Verweij, J., de Jonge, M. J. A.

“…Purpose There are several reasons why combining an inhibitor of the vascular endothelial and the platelet-derived growth factor receptor with a taxane might…”
Get full text

Imatinib treatment of poor prognosis mesenchymal-type primary colon cancer: a proof-of-concept study in the preoperative window period (ImPACCT) by Ubink, I, Bloemendal, H J, Elias, S G, Brink, M A, Schwartz, M P, Holierhoek, Y C W, Verheijen, P M, Boerman, A W, Mathijssen, R H J, de Leng, W W J, de Weger, R A, van Grevenstein, W M U, Koopman, M, Lolkema, M P, Kranenburg, O, Borel Rinkes, I H M

“…The identification of four Consensus Molecular Subtypes (CMS1-4) of colorectal cancer forms a new paradigm for the design and evaluation of subtype-directed…”
Get full text

Role of genetic variation in docetaxel-induced neutropenia and pharmacokinetics by Nieuweboer, A J M, Smid, M, de Graan, A-J M, Elbouazzaoui, S, de Bruijn, P, Eskens, F A L M, Hamberg, P, Martens, J W M, Sparreboom, A, de Wit, R, van Schaik, R H N, Mathijssen, R H J

“…Docetaxel is used for treatment of several solid malignancies. In this study, we aimed for predicting docetaxel clearance and docetaxel-induced neutropenia by…”
Get full text

Renal Function as a Predictor of Irinotecan-induced Neutropenia by Jong, FA, Bol, JM, Mathijssen, RHJ, Gelder, T, Wiemer, EAC, Sparreboom, A, Verweij, J

“…Although approximately half of the administered dose of irinotecan is recovered in urine, scarce data are available on the association of renal function with…”
Get full text

Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study by Groenland, S.L., van Eerden, R.A.G., Westerdijk, K., Meertens, M., Koolen, S.L.W., Moes, D.J.A.R., de Vries, N., Rosing, H., Otten, H., Vulink, A.J.E., Desar, I.M.E., Imholz, A.L.T., Gelderblom, H., van Erp, N.P., Beijnen, J.H., Mathijssen, R.H.J., Huitema, A.D.R., Steeghs, N.

“…Oral targeted therapies show a high pharmacokinetic (PK) interpatient variability. Even though exposure has been positively correlated with efficacy for many…”
Get full text